Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 3940-3947

  Quenelle, Debra C ^a,d   Collins, Deborah J ^a   Herrod, Bridgett P ^a   Keith, Kathy A ^a   Trahan, Julissa ^b,c   Beadle, James R ^b,c   Hostetler, Karl Y ^b,c   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ANTIVIRUS AGENT; CIDOFOVIR; HEXADECYLOXYPROPYL [9 (3 HYDROXY 2 PHOSPHONYLMETHOXYPROPYL)ADENINE]; OCTADECYLOXYETHYL [9 (3 HYDROXY 2 PHOSPHONYLMETHOXYPROPYL)ADENINE]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COWPOX; COWPOX VIRUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; COWPOX; KIDNEY; LIVER; LUNG; MICE; MOLECULAR STRUCTURE; PHOSPHONIC ACIDS; SPLEEN; VACCINIA VIRUS;

EID: 35848929516     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00184-07     Document Type: Article

References (28)

1. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 57:13-23.
2. Beadle, J. R., C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
3. Beadle, J. R., W. B. Wan, S. L. Ciesla, K. A. Keith, C. Hartline, E. R. Kern, and K. Y. Hostetler. 2006. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem. 49:2010-2015.
4. Bijsterbosch, M. K., L. J. J. W. Smeijsters, and T. J. C. van Berkel. 1998. Disposition of the acyclic nucleoside phosphonate (S)-9(3-hydroxy-2-phosphonylmethoxypropyl)adenine. Antimicrob. Agents Chemother. 42: 1146-1150.
5. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474-481.
6. Ciesla, S. L., J. Trahan, W. B. Wan, J. R. Beadle, K. A. Aldern, G. R. Painter, and K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res. 59:163-171.
7. Cundy, K. C., A. M. Bidgood, G. Lynch, J. P. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24:745-752.
8. Dal Pozzo, F., G. Andrei, I. Lebeau, J. R. Beadle, K. Y. Hostetler, E. De Clercq, and R. Snoeck. 2007. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antivir. Res. 75:52-57.
9. De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:382-397.
10. De Clercq, E., A. Holy, and I. Rosenberg. 1989. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother. 33:185-191.
11. De Clercq, E., A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.
12. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holy. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res. 8:261-272.
13. Hartline, C. B., K. M. Gustin, W. B. Wan, S. L. Ciesla, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2005. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis. 191:396-399.
14. Keith, K. A., M. J. Hitchcock, W. A. Lee, A. Holy, and E. R. Kern. 2003. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 47: 2193-2198.
15. Kern, E. R. 2003. In vitro activity of potential anti-poxvirus agents. Antivir. Res. 57:35-40.
16. Kern, E. R. 2006. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antivir. Res. 71:164-171.
17. Kern, E. R., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and D. C. Quenelle. 2004. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:3516-3522.
18. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.
19. Lebeau, I., G. Andrei, F. Dal Pozzo, J. R. Beadle, K. Y. Hostetler, E. De Clerq, J. van den Oord, and R. Snoeck. 2006. Activities of alkoxyalkyl esters
20. of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2- phosphonylmethoxy-propyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 50:2525-2529.
21. Painter, G. R., and K. Y. Hostetler. 2004. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 8:423-427.
22. Quenelle, D. C., D. J. Collins, and E. R. Kern. 2003. Efficacy of multiple- and single-dose cidofovir in vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 47:3275-3280.
23. Quenelle, D. C., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinina virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
24. Smeijsters, L. J., H. Nieuwenhuijs, R. C. Hermsen, G. M. Dorrestein, F. F. Franssen, and J. P. Overdulve. 1996. Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice. Antimicrob. Agents Chemother. 40:1584-1588.
25. Snoeck, R., A. Holy, C. Dewolf-Peeters, J. Van Den Oord, E. De Clercq, and G. Andrei. 2002. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:3356-3361.
26. Snoeck, R., T. Sakuma, E. De Clercq, I. Rosenberg, and A. Holy. 1988. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1839-1844.
27. Wachsman, M., B. G. Petty, K. C. Cundy, H. S. Jaffe, P. E. Fisher, A. Pastelak, and P. S. Lietman. 1996. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antivir. Res. 29:153-161.
28. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. M. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.